drugset / Trial / NCT05783089
MSLN-targeted CAR-T Cells in Solid Tumors.
Phase 1
Not yet recruiting
87 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to explore the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cells in subjects with Mesothelin-positive advanced malignant solid tumors.
Timeline
- Start
- 2023-04
- Primary completion
- 2025-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-mesothelin CAR-T cells | Cell therapy | 0.1 cells/kg | Intravenous |
| Subject | Anti-mesothelin CAR-T cells | Cell therapy | 2 cells/kg | Intravenous |